Inhibition of DNA Methylation by 1-Hr Infusion of 5-aza-2'-Deoxycitidine (Decitabine) x 10 Days (M-F) With Escalating Doses of Sub-Q Pegylated (PEG) Interferon-alpha 2B (PEG-Intron): A Phase I Study With Molecular Correlates

Trial Profile

Inhibition of DNA Methylation by 1-Hr Infusion of 5-aza-2'-Deoxycitidine (Decitabine) x 10 Days (M-F) With Escalating Doses of Sub-Q Pegylated (PEG) Interferon-alpha 2B (PEG-Intron): A Phase I Study With Molecular Correlates

Discontinued
Phase of Trial: Phase I

Latest Information Update: 13 Dec 2013

At a glance

  • Drugs Decitabine (Primary) ; Peginterferon alfa-2b (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 03 Jun 2013 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 12 Oct 2010 Actual end date (Mar 2010) added as reported by ClinicalTrials.gov.
    • 12 Oct 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top